Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study-Reference-Cited by-同舟云学术

Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study

Published:2022-01-04 Issue:6 Volume:63 Page:1398-1406
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Gadaud Noémie¹,Leroy Harmony²,Bérard Emilie³⁴,Tavitian Suzanne¹,Leguay Thibaut²,Dimicoli-Salazar Sophie²,Rieu Jean-Baptiste⁵,Luquet Isabelle⁵,Largeaud Laetitia⁵⁶⁷,Bidet Audrey⁸,Delabesse Eric⁵⁶⁷,Klein Emilie⁸,Sarry Audrey¹,de Grande Anne-Charlotte²,Bories Pierre¹,Pigneux Arnaud²⁹¹⁰,Récher Christian¹⁶⁷,Dumas Pierre-Yves²⁹¹⁰,Bertoli Sarah¹⁶⁷

Affiliation:

1. Service d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

2. Centre Hospitalier Universitaire de Bordeaux, Service d’Hématologie Clinique et de Thérapie Cellulaire, Bordeaux, France

3. Service d’Epidémiologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France

4. CERPOP, Université de Toulouse, Inserm, UPS, Toulouse, France

5. Laboratoire d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

6. Université Toulouse III Paul Sabatier, Toulouse, France

7. Cancer Research Center of Toulouse, UMR1037 INSERM, ERL5294 CNRS, Toulouse, France

8. Laboratoire d’Hématologie Biologique, CHU Bordeaux, Bordeaux, France

9. Université de Bordeaux, Bordeaux, France

10. Institut National de la Santé et de la Recherche Médicale, Bordeaux, France

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.2022140

Reference27 articles.

1. 5-azacytidine in acute leukemia

2. Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

3. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

4. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

5. Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy;Cancer Medicine;2024-02

2. Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study;Leukemia Research;2024-01

3. Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients;European Journal of Haematology;2023-11-29